Inflammatory Phenotypes In Severe Pneumonia: Clinical Evidence To Mouse Models For Precision Therapeutics.

Summary

Latent class analysis of 548 ICU patients with pulmonary sepsis identified hyperinflammatory and hypoinflammatory phenotypes with distinct lung injury and mortality profiles. A pneumococcal pneumonia mouse model reproduced divergent inflammatory trajectories, and dexamethasone or IL-6 receptor blockade provided therapeutic benefit selectively in the more inflamed phenotype.

Key Findings

• Latent class analysis of 548 critically ill patients with pulmonary sepsis identified hyperinflammatory and hypoinflammatory phenotypes.
• The hyperinflammatory phenotype was associated with greater lung injury and higher mortality.
• A pneumococcal pneumonia mouse model reproduced divergent phenotypes, and anti-inflammatory therapy was beneficial exclusively in the more inflamed mice.

Clinical Implications

Routine or trial-based inflammatory biomarker classification may help identify patients who are more likely to benefit from corticosteroids or IL-6 pathway blockade, rather than applying immunomodulation uniformly to all patients with severe pneumonia or ARDS.

Limitations

• The clinical analysis was observational and cannot establish that phenotype-guided treatment improves patient outcomes.
• Mouse phenotypes may not capture the full biological and treatment complexity of human pulmonary sepsis.
• The provided data do not report the duration of clinical follow-up or the complete biomarker classifier performance.

Future Directions

Prospective biomarker-stratified clinical trials should test whether corticosteroids, IL-6 pathway inhibitors, or other immunomodulators improve outcomes specifically in hyperinflammatory patients. Further work should validate classifier portability across infection sources, institutions, and ARDS subphenotypes.